サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1512669

プロバイオティクスIBSサプリメントの世界市場：2024年～2031年

Global Probiotic IBS Supplements Market - 2024-2031

出版日
ページ情報
英文 235 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
プロバイオティクスIBSサプリメントの世界市場：2024年～2031年
出版日: 2024年07月10日
発行: DataM Intelligence
ページ情報: 英文 235 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

プロバイオティクスIBSサプリメントの世界市場は、2023年に2,912万米ドルに達し、2031年には4,879万米ドルに達すると予測され、予測期間2024年～2031年のCAGRは7.65%で成長する見込みです。

プロバイオティクスは過敏性腸症候群の症状を緩和する可能性を示しています。米国消化器病学会（American College of Gastroenterology）のメタ分析によると、プロバイオティクスは腹部膨満感や鼓腸などのIBS症状全般の改善に役立つ可能性があります。プロバイオティクス市場の拡大を後押ししているのは、腸の健康に役立つという消費者の意識の高まり、消化器系疾患の罹患率の増加、そしてプロバイオティクスが消化だけにとどまらず健康に及ぼす潜在的影響についての継続的な探求です。

IBSの症状管理など、消化器系の健康に対するプロバイオティクスの潜在的なメリットに対する消費者の意識が高まっています。プロバイオティクスと腸の健康促進におけるその役割についてより多くの人々が知るようになるにつれ、特にIBSのような症状に関連したプロバイオティクス・サプリメントの需要が高まり、世界の市場成長を牽引しています。

北米は世界のプロバイオティクスIBSサプリメント市場を独占しています。北米では様々な用途でプロバイオティクスサプリメントが多く使用されており、この地域の市場拡大を積極的に改善しています。国際食品情報評議会が2022年4月に実施した「食品と健康に関する調査」によると、米国では回答者の約33%が食生活にプロバイオティクスを取り入れる努力をしており、そのうち60%が毎日取り入れることを目標としています。

ダイナミクス

過敏性腸症候群の有病率の上昇

世界の過敏性腸症候群の罹患率の上昇は、プロバイオティクス・サプリメント市場の重要な促進要因です。国際胃腸障害財団によると、IBSの世界の推定値は人口の5～10％と報告されています。同様に、2023年9月、シーダーズ・サイナイの研究者らによる新たな研究の結果、過敏性腸症候群は以前考えられていたよりも蔓延していることが明らかになった。消化器内科を受診する人の約20～40％がIBS症状によるものです。

IBSと診断される人が増えるにつれて、効果的な管理と緩和の選択肢に対する需要が高まっており、プロバイオティクスは腸の健康に役立つと考えられているため、好ましい選択肢の一つです。IBSのような健康状態の管理には、自然でホリスティックなアプローチを好む人が多いです。健康的な腸内細菌叢を促進する有益な細菌から成るプロバイオティクスは、このような自然療法への嗜好によく合致しています。

増加するプロバイオティクスの利用

プロバイオティクスは、腸内細菌叢のバランスを維持し、免疫機能をサポートすることで、消化器系の健康を促進する可能性があることで知られています。プロバイオティクスの利点に関する消費者の意識の高まりは、消化器系の健康を含む様々な応用分野におけるプロバイオティクスの幅広い消費を促進しています。

国際食品情報協議会（International Food Information Council）が2021年に実施した調査では、アメリカ人の51％が腸の健康を促進するためにプロバイオティクスを食生活に取り入れ、33％が免疫機能を強化するためにプロバイオティクスを使用し、38％が総合的な健康とウェルネスを目的としてプロバイオティクスを取り入れ、13％が感情的な幸福をサポートするためにプロバイオティクスを摂取していると回答しています。

プロバイオティクスは、IBS患者では乱れがちな腸内細菌のバランスを回復させるのに役立つと考えられています。一部の研究では、特定のプロバイオティクス菌株が、腸内細菌叢の構成を調整し、炎症を抑え、腸管バリア機能を改善することによって、IBS症状の緩和に役立つ可能性が示唆されています。NIHによると、IBS患者に対するプロバイオティクスの影響を評価するメタ分析が数多く行われており、その大半はプロバイオティクスが症状の緩和にプラスに働くと結論づけています。

医薬品治療との競合

プロバイオティクスのサプリメントは、IBS症状を管理するための自然でホリスティックなアプローチを提供する一方で、医薬品治療との競合に直面しています。抗痙攣薬、下剤、抗うつ薬などの治療薬は、IBS治療のために一般的に処方されています。医薬品による治療は、プロバイオティクスのサプリメントとは症状管理へのアプローチが異なります。

薬物治療は通常、特定の症状や症状の根本的なメカニズムをターゲットにします。腹痛、腹部膨満感、不規則な排便などの症状をより即効的に緩和します。また、医療専門家によって処方されることが多いため、症状の緩和を求める患者にとって、安心感と指導を得ることができます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 過敏性腸症候群の有病率の増加
      • プロバイオティクスの使用増加
    • 抑制要因
      • 医薬品治療との競合
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • DMIの見解

第6章 COVID-19分析

第7章 菌株別

  • 乳酸菌
  • ビフィズス菌
  • その他

第8章 形状別

  • 錠剤
  • カプセル
  • 液体
  • 粉末
  • その他

第9章 流通チャネル別

  • スーパーマーケット／ハイパーマーケット
  • 薬局/健康ストア
  • オンラインストア
  • その他

第10章 エンドユーザー別

  • 乳幼児
  • 小児
  • 大人
  • 高齢者

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • The Good Bug
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Zeroharm Sciences Private Limited
  • Menoveda Life Sciences Private Limited
  • Unique Biotech Limited
  • Projoy Pvt Ltd
  • Pure NSM-Nutritional Supplement Manufacturers, Inc.
  • Nature's Bounty
  • Hyperbiotics
  • Advanced Vital Enzymes Private Ltd
  • Wren Laboratories Ltd

第14章 付録

目次
Product Code: FB8516

Overview

Global Probiotic IBS Supplements Market reached US$ 29.12 million in 2023 and is expected to reach US$ 48.79 million by 2031, growing with a CAGR of 7.65% during the forecast period 2024-2031.

Probiotics have shown a potential to relieve irritable bowel syndrome symptoms. An American College of Gastroenterology meta-analysis found that probiotics may help improve overall IBS symptoms, including bloating and flatulence. The expansion of the probiotics market is propelled by heightened consumer awareness of the benefits to gut health, a growing incidence of digestive disorders, and continuous exploration of probiotics' potential health impacts extending beyond digestion.

There's a heightened awareness among consumers regarding the potential benefits of probiotics for digestive health, including managing symptoms of IBS. As more people become familiar with probiotics and their role in promoting gut health, the demand for probiotic supplements, specifically related to conditions like IBS, increases driving the market growth worldwide.

North America dominates the global probiotic IBS supplements market. The high use of probiotic supplements in various aspects of application in North America is positively improving the market expansion in this region. According to the Food and Health Survey conducted by the International Food Information Council in April 2022, around 33% of respondents in the United States make an effort to include probiotics in their diets, with 60% aiming to do so daily.

Dynamics

Increasing Prevalence of Irritable Bowel Syndrome

The rising incidence of IBS worldwide is a significant driver for the probiotic supplements market. According to the International Foundation for Gastrointestinal Disorders, the worldwide estimation of IBS is reported to be 5-10% of the population. Similarly, in September 2023, results from a new study by Cedars-Sinai investigators revealed that irritable bowel syndrome is more prevalent than previously thought. Approximately 20 to 40% of all visits to gastroenterologists are due to IBS symptoms.

As more individuals are diagnosed with IBS, there's a growing demand for effective management and relief options, with probiotics being one of the preferred choices due to their perceived benefits in gut health. Many individuals prefer natural and holistic approaches to managing health conditions like IBS. Probiotics, which consist of beneficial bacteria that promote a healthy gut microbiota, align well with this preference for natural remedies.

Rising Use of Probiotics

Probiotics are known for their potential to promote digestive health by maintaining a balanced intestinal microbiota and supporting immune function. Increasing consumer awareness regarding the benefits of probiotics is driving the wide consumption of probiotics in various application sectors including digestive health.

In a 2021 survey conducted by the International Food Information Council, findings indicated that 51% of Americans incorporate probiotics into their diets to promote gut health, 33% use them to bolster immune function, 38% integrate probiotics for overall health and wellness purposes, and 13% reported consuming probiotics to support emotional well-being.

Probiotics are believed to help restore the balance of gut bacteria, which can be disrupted in individuals with IBS. Some studies suggest that certain probiotic strains may help relieve IBS symptoms by modulating gut microbiota composition, reducing inflammation and improving intestinal barrier function. According to NIH, numerous meta-analyses have evaluated the impact of probiotics on individuals with IBS with the majority concluding that probiotics offer a positive effect in alleviating symptoms.

Competition from Pharmaceutical Treatments

While probiotic supplements offer a natural and holistic approach to managing IBS symptoms, they face competition from pharmaceutical treatments. The treatments such as antispasmodics, laxatives and antidepressants, are commonly prescribed for IBS management. Pharmaceutical treatments offer a different approach to symptom management compared to probiotic supplements.

Pharmaceutical treatments typically target specific symptoms or underlying mechanisms of the condition. They provide more immediate relief of symptoms such as abdominal pain, bloating, and irregular bowel movements. In addition, they are often prescribed by healthcare professionals, providing a level of assurance and guidance for patients seeking symptom relief.

Segment Analysis

The global probiotic IBS supplements market is segmented based on strain, form, distribution channel, end-user and region.

Potential Benefits of Bifidobacterium

The global probiotic IBS supplements market is segmented based on strain into lactobacillus, bifidobacterium and others. The bifidobacterium segment accounted for the largest share of the global market. Bifidobacterium strains, such as Bifidobacterium infantis and Bifidobacterium longum, have been extensively studied for their potential benefits in managing symptoms of IBS.

Clinical trials and research studies have consistently shown positive outcomes, including improved abdominal pain, bloating and bowel habits. According to Harvard studies, Bifidobacterium bifidum MIMBb75, probiotic strain, has demonstrated strong adherence to intestinal cells, suggesting it may effectively modify the gut microbiota and enhance the intestinal barrier.

Clinical trials published in Alimentary Pharmacology & Therapeutics have shown that daily supplementation with Bifidobacterium bifidum MIMBb75 significantly improved overall IBS symptoms, as well as individual symptoms like abdominal pain, bloating and fecal urgency. Also, recent research has indicated that even heat-inactivated Bifidobacterium bifidum MIMBb75 can relieve IBS symptoms.

Geographical Penetration

High Prevalence of Irritable Bowel Syndrome in North America

North America dominates the global probiotic IBS supplements market. North America has a relatively high prevalence of irritable bowel syndrome, with millions of individuals affected by this condition. The International Foundation for Gastrointestinal Disorders recently reported that IBS affects between 25 and 45 million people in United States. About 2 in 3 IBS sufferers are female, while 1 in 3 IBS sufferers are male.

The large patient population creates a significant market opportunity for products targeting IBS management. With a strong culture of health and wellness in North America, many consumers actively seek natural and holistic approaches to managing health conditions like IBS. Probiotic supplements are perceived as safe and effective options for promoting digestive health and alleviating symptoms of IBS, fitting well with the preferences of health-conscious consumers in the region.

Competitive Landscape

The major global players in the market include The Good Bug, Zeroharm Sciences Private Limited, Menoveda Life Sciences Private Limited, Unique Biotech Limited, Projoy Pvt Ltd, Pure NSM - Nutritional Supplement Manufacturers, Inc., Nature's Bounty, Hyperbiotics, Advanced Vital Enzymes Private Ltd and Wren Laboratories Ltd.

COVID-19 Impact Analysis

The COVID-19 had a moderate impact on the global probiotic IBS supplements market. The probiotic supplements market, like many other industries, has been impacted by disruptions in global supply chains caused by the pandemic. Restrictions on travel, closures of manufacturing facilities and logistical challenges have led to delays in production and distribution, affecting the availability of probiotic products in some regions.

The pandemic has heightened awareness about the importance of maintaining a healthy immune system. Probiotics, known for their role in gut health, have gained attention for their potential immune-supporting properties. The greater demand for products perceived to promote overall health positively impacted the probiotic supplements market. Individuals with IBS are motivated to explore natural remedies like probiotics to support their immune and digestive health.

By Strain

  • Lactobacillus
  • Bifidobacterium
  • Other

By Form

  • Tablet
  • Capsules
  • Liquid
  • Powder
  • Others

By Distribution Channel

  • Supermarkets/Hypermarkets
  • Pharmacy/Health Stores
  • Online Stores
  • Other

By End-User

  • Infant
  • Children
  • Adults
  • Seniors

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Russia
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In August 2023, Hyperbiotics introduced PRO-IBS Support. This innovative product features a dual-action synergistic blend of Lactiplantibacillus plantarum 299v and highly bioavailable Boswellia serrata extract. The formulation aims to effectively alleviate gut discomfort and dysfunction in individuals with IBS.
  • In August 2022, researchers at the University of Nottingham secured £1.8 million in funding for a three-year project to explore the potential benefits of cellulose-based food supplements for individuals suffering from Irritable Bowel Syndrome, focusing on colon fermentation.

Why Purchase the Report?

  • To visualize the global probiotic IBS supplements market segmentation based on strain, form, distribution channel, end-user and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of probiotic IBS supplements market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global probiotic IBS supplements market report would provide approximately 70 tables, 76 figures and 235 pages.

Target Audience 2024

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Strain
  • 3.2. Snippet by Form
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by End-User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Prevalence of Irritable Bowel Syndrome
      • 4.1.1.2. Rising Use of Probiotics
    • 4.1.2. Restraints
      • 4.1.2.1. Competition from Pharmaceutical Treatments
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Strain

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Strain
    • 7.1.2. Market Attractiveness Index, By Strain
  • 7.2. Lactobacillus
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Bifidobacterium
  • 7.4. Other

8. By Form

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 8.1.2. Market Attractiveness Index, By Form
  • 8.2. Tablet
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Capsules
  • 8.4. Liquid
  • 8.5. Powder
  • 8.6. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Supermarkets/Hypermarkets
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Pharmacy/Health Stores
  • 9.4. Online Stores
  • 9.5. Other

10. By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.1.2. Market Attractiveness Index, By End-User
  • 10.2. Infants
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Children
  • 10.4. Adults
  • 10.5. Seniors

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Strain
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Strain
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Strain
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Strain
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Strain
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. The Good Bug
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Zeroharm Sciences Private Limited
  • 13.3. Menoveda Life Sciences Private Limited
  • 13.4. Unique Biotech Limited
  • 13.5. Projoy Pvt Ltd
  • 13.6. Pure NSM - Nutritional Supplement Manufacturers, Inc.
  • 13.7. Nature's Bounty
  • 13.8. Hyperbiotics
  • 13.9. Advanced Vital Enzymes Private Ltd
  • 13.10. Wren Laboratories Ltd

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us